Radioimmunotherapy in Lymphomas

Reem Karmali*, Stephanie A. Gregory

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Radioimmunotherapy (RIT) studies demonstrate favorable efficacy and safety profiles in follicular lymphoma with the primary toxicity being reversible myelosuppression. Many studies have demonstrated higher overall response rates and durations of response when used earlier in the treatment algorithm for follicular or indolent lymphoma. This chapter asks a number of questions that will drive home the nuances of RIT use. It commences with a discourse on the criteria which excludes a patient from receiving RIT. The consolidation in aggressive lymphomas are encouraging but should not be adopted as a standard approach outside of a clinical trial.

Original languageEnglish (US)
Title of host publicationCancer Consult
Subtitle of host publicationExpertise for Clinical Practice
PublisherWiley-Blackwell
Pages398-402
Number of pages5
ISBN (Electronic)9781118589199
ISBN (Print)9781118589212
DOIs
StatePublished - Jun 20 2014

Keywords

  • Follicular lymphoma
  • Lymphomas
  • Mantle cell lymphoma (MCL)
  • Radioimmunotherapy (RIT)

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Radioimmunotherapy in Lymphomas'. Together they form a unique fingerprint.

Cite this